CYTK

CYTOKINETICS INC

Health Care·Biotechnology·$8.1B

Reported·Q2-2015

Cytokinetics Misses on Revenue, Stock Down 4.59%

Metric	Actual	Expected	Surprise
EPS	$-0.27	N/A	+3.57%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

More Earnings This Week

AREReported

ALEXANDRIA REAL ESTA REIT

Jul 27, 2015

CDNSReported

CADENCE DESIGN SYS I

Jul 27, 2015

ADCReported

AGREE RLTY CORP REIT

Jul 27, 2015

MPWRReported

MONOLITHIC PWR SYS I

Jul 27, 2015

NSC

Management Commentary

Tone: Defensive

Management expressed concern over current market conditions. They did not provide any specific guidance for future quarters.

Management did not provide specific revenue figures during the call.

The company acknowledged ongoing challenges in the market.

What It Means

Cytokinetics reported a loss of $0.27 per share, which was slightly better than expected. However, the lack of revenue information and no guidance led to a negative stock reaction, with shares dropping 4.59%. Investors may be cautious due to uncertainties in the company's future performance.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime